Although currently there are not sufficient data to compare responses to immunotherapy among different ethnicities since only 1–2% of the participants in the published immunotherapy clinical trials are African Americans [59, 60], our results suggest African American NSCLC patients may have an overall higher response rate due to ethnicity-specific JAK3 mutations. This evidence concerns the gene JAK3 and non-small cell lung carcinoma.